A vaccine that can learn and adapt sounds like salvation. Until it starts changing more than the virus.
In a pandemic, the world does not need a miracle. It needs a result.
London, early 2020. COVID-19 is tearing through St. Margaret’s Hospital, and Dr. Sofia Mendes is running on exhaustion and instinct. Wards overflow. Supplies vanish. Patients die alone. Every shift feels like a slow disaster nobody can stop.
When lockdown hits, and the system begins to fracture, Sofia makes a decision she can’t take back. Alongside her colleague Claire Thompson, she turns a forgotten hospital room into a hidden lab, reviving her abandoned research project, Vitalis Redux, a radical decoy-protein platform designed to disrupt viral replication at its source. When Claire succumbs to the virus, grief turns Sofia’s mission into something sharper and far more aggressive.
Outmatched and under-resourced, Sofia brings in her former research partner, Dr. Jolie Harding. She draws in private investor Magnus Vale, whose funding brings speed, scale, and a level of pressure Sofia cannot control. The faster the results arrive, the less room there is for caution. Together, they attempt something unprecedented: an adaptive vaccine built to evolve alongside the virus, and whatever comes next.
Approval comes. Rollout follows. The world celebrates. Then silence. Sofia starts to see perfection in the data, suggesting the cure has not just ended an emergency, but rewriting the future.
A tense medical thriller for readers of Robin Cook and Michael Crichton, Remnavax: The Discovery is the first novel in a grounded medical thriller trilogy set in the lived reality of the COVID era, where scientific ambition collides with institutional power, and victory carries a cost no one is ready to name.
Publisher: BookFuel
D. K. Rivers is a London-based banker and writer whose fiction explores the intersections of memory, time, and institutional power. Drawing on a career in finance and a long-standing fascination with complex systems - both human and structural - his work examines how organizations behave under pressure, how decisions are shaped by invisible incentives, and how individual lives are altered by forces far larger than themselves.His writing is grounded in emotional realism and informed by close observation of professional environments where precision, risk, and moral ambiguity coexist. Across speculative fiction and corporate thrillers, Rivers is interested less in spectacle than in consequence: what happens after the breakthrough, after the decision, after the system declares success.Remnavax: The Discovery is the culmination of several years of research and reflection following the COVID-19 pandemic. Set in London during the earliest months of the COVID crisis, the novel blends scientific plausibility with moral urgency, exploring the human cost of innovation and the ethical fault lines brought to breaking point when institutions are forced to move faster than they were designed to. The book draws on real-world medical, regulatory, and organizational pressures while remaining firmly rooted in character and lived experience.Remnavax: The Discovery, is his first novel.
